• Clinical Introduction
• 49 min
  1. Frontotemporal dementia

  • Prof. Bruce Miller
• 57 min
  2. Parkinson disease

  • Prof. Stanley Fahn
• 35 min
  3. Atypical parkinsonian syndromes

  • Dr. David Burn
• 40 min
  4. Huntington's disease

  • Prof. Roger Barker
• Neuroimaging
• 22 min
  5. Molecular brain imaging (PET) in diseases with dementia

  • Prof. Karl Herholz
• Pathology, Genetic and Molecular Aspects (1)
• 42 min
  6. A molecular understanding of Alzheimer's disease

  • Prof. John Hardy
• 33 min
  7. Neuropathology of neurodegenerative disorders

  • Prof. Jillian Kril
• 52 min
  8. The role of MAPT (Tau) in neurodegenerative disease: one bullet with many triggers

  • Dr. Michael Hutton
• 12 min
  9. Ubiquitination and Alzheimer related disorders

  • Prof. John Mayer
• Pathology, Genetic and Molecular Aspects (2)
• 46 min
  10. The molecular biology of Huntington's disease

  • Prof. David C. Rubinsztein
• 46 min
  11. Metals, oxidative stress and neurodegeneration

  • Prof. Ashley Bush
• Latest Developments in the Field
• 46 min
  12. Animal models of tauopathy

  • Prof. David Westaway
• 61 min
  13. Parkinson's disease and transplants

  • Prof. Roger Barker
• Archived Lectures *These may not cover the latest advances in the field
• 29 min
  14. Neuropathology of neurodegenerative disorders

  • Prof. Jillian Kril
• 36 min
  15. Motor neurone disease: molecular basis

  • Prof. Kevin Talbot
• 51 min
  16. Alzheimer's disease (AD)

  • Prof. John Hodges
• 53 min
  17. Frontotemporal dementia syndromes

  • Prof. John Hodges
• 38 min
  18. Motor neurone disease: clinical aspects

  • Prof. Kevin Talbot
• 26 min
  19. Neuro-imaging in dementia: using MRI in routine work-up

  • Prof. Philip Scheltens
• 53 min
  20. Prion diseases

  • Prof. Pierluigi Gambetti
• 38 min
  21. Mitochondrial disorders and neurodegeneration

  • Prof. Anthony Schapira
• 21 min
  22. Neurodegenerative disease: expression levels of normal sequence pathogenic proteins contribute to risk of disease

  • Prof. John Hardy
• 44 min
  23. Mutations in parkinsonian syndromes

  • Dr. Andrew Singleton
• 42 min
  24. Experimental therapies in Alzheimer's disease: the development and use of mouse models

  • Prof. David Westaway
• 32 min
  25. Frontotemporal dementia

  • Prof. Bruce Miller

Printable Handouts

PDF

Navigable Slide Index

1. Intro slide
2. An essay on the shaking palsy
3. Outline 1
4. Difference between parkinsonism and PD
5. Parkinsonism vs. Parkinson disease
6. The six cardinal features of parkinsonism
7. Defining Parkinson disease
8. Definition of PD
9. Clinical definition of Parkinson disease
10. Pathological and biochemical basis of PD
11. Pathological and biochemical definition of PD
12. Lewy bodies in a SN pigmented neuron
13. Staging of brain pathology related to sporadic PD
14. More pathological and biochemical features of PD
15. Diagram of the nigrostriatle dopamine neurons
16. Horizontal slice through the brain
17. Neuroimaging of PD
18. Definition of PD by PET/SPECT scans
19. FDOPA PET in PD
20. FPCIT/PET
21. Outline 2
22. Age-specific prevalence in PD
23. Age specific prevalence of incidental Lewy bodies
24. Age- and sex- specific incidence rate of PD
25. Prevalence of PD in the USA
26. Projections for PD prevalence in the USA
27. Outline 3
28. Consequences of putaminal DA deficiency
29. Metabolic activities in the brain in PD
30. Outline 4
31. Rate of clinical progression
32. Gene localizations identified for PD
33. The very "benign" parkinsonian patient
34. Outline 5
35. Parkinsonian states
36. Secondary Parkinson
37. Parkinson plus syndromes
38. Heredodegenerative parkinsonism
39. Clinical instruments to measure severity of PD
40. Unified PD rating scale (UPDRS)
41. UPRS determine cause of parkinsonism (I)
42. UPRS determine cause of parkinsonism (II)
43. UPRS determine cause of parkinsonism (II)
44. Outline 6
45. Dopaminergic agents
46. Biochemical pathway for formation of dopamine
47. Non-dopaminergic agents for motor symptoms
48. Non-dopaminergic agents for non-motor symptoms
49. PD is more then loss of striatal dopamine
50. Non-motor problems of Parkinson's disease (I)
51. Non-motor problems of Parkinson's disease (II)
52. Treatment strategy
53. Complications of therapy
54. Motor complications appearance
55. Frequency of motor response complications
56. Dopamine receptors
57. Outline 7
58. Composite of progression of PD
59. Slowing progression
60. Neuroprotective therapy
61. Etiology of PD
62. Thank you

Topics Covered

• Clinical symptoms of PD
• Current knowledge on pathological mechanisms
• Epidemiological facts
• Genetic factors
• Clinical management and DA replacement therapy
• Importance of nonmotor symptoms
• Future treatment directions

Links

Series:

• Neurodegenerative Diseases

Categories:

• Clinical Practice
• Neuroscience

Therapeutic Areas:

• Neurology

Talk Citation

Publication History

• Published on October 1, 2007

Financial Disclosures

• Prof. Stanley Fahn has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.